Summary

This phase II trial tests whether vidutolimod with nivolumab works to destroy tumor cells in patients with castration resistant prostate cancer that has spread to other places in the body (metastatic). Nivolumab is an antibody working by attaching to and blocking a molecule called PD 1. PD 1 is a protein that is present on different types of cells in the immune system and controls parts of the immune system by shutting it down. Antibodies (proteins in the immune system which act to stop infection harming the body) that block PD 1 can potentially prevent PD 1 from shutting down the immune system, thus allowing immune cells to recognize and destroy cancer cells. Vidutolimod (CMP-001) is a Toll-like receptor 9 (TLR9) agonist, with the ability to generate tumor-targeted T cells capable of killing a tumor both locally and systemically in combination with checkpoint inhibitors (nivolumab, in this case), thus potentially improving outcomes for people whose tumors are progressing. Giving nivolumab and vidutolimod may kill more cancer cells in patients with metastatic prostate cancer.

Objectives

PRIMARY OBJECTIVE:
I. To evaluate the safety and tolerability of vidutolimod (CMP-001) in combination with nivolumab in patients with metastatic castration resistant prostate cancer.

SECONDARY OBJECTIVES:
I. To evaluate prostate-specific antigen (PSA) response rate.
II. To evaluate PSA undetectable rate.
III. To evaluate time to PSA progression according to PCWG3.
IV. To evaluate the confirmed objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.
V. To evaluate the 1-year radiographic progression free survival (rPFS) according to PCWG3.
VI. To determine the 1-year overall survival (OS).
VII. To evaluate the confirmed ORR by immune-related RECIST (irRECIST).

EXPLORATORY OBJECTIVES:
I. To evaluate the effect of treatment on the following changes, and others:
Ia. Numbers of CD8 T-cells in tumors;
Ib. Dendritic cell activation status (CD80, CD86, CD40) in tissue biopsy;
Ic. Tumor specific T-cells in the blood (human leukocyte antigen [HLA]-DR+/CD38+ with T-cell receptor [TCR] sequencing).

OUTLINE:
Patients receive vidutolimod subcutaneously (SC) on days 1 and 7 of cycle 1, intratumorally (IT) on day 14 of cycle 1 and days 1 and 14 of cycle 2, and then SC on day 1 of subsequent cycles. Patients also receive nivolumab intravenously (IV) over 30 minutes on days 1 and 14 of cycle 2 and on day 1 of subsequent cycles. Cycles of nivolumab repeat every 4 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity. Cycles of vidutolimod repeat every 4 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity.

After completion of the study treatment, patients are followed up for 30 days and then every 12 weeks thereafter.

Eligibility

1. Male >= 18 years of age
2. Histologically confirmed adenocarcinoma of the prostate with metastatic disease
3. Subjects who are refractory to a novel antiandrogen therapy (abiraterone, darolutamide, enzalutamide and/or apalutamide) and have failed at least 1 taxane based chemotherapy regimen (or who are deemed medically unsuitable to be treated with a taxane regimen or have actively refused treatment with a taxane regimen)
4. Prior orchiectomy or serum testosterone levels < 50 ng/dL determined within 4 weeks prior to start of study drug
5. Having measurable disease per RECIST 1.1 (at least one additional lesion >= 0.5 cm amenable to repeated IT injection per investigator)
6. Eastern Cooperative Oncology Group performance status of 0 or 1
7. Neutrophil count >= 1,000/mm^3 (within 4 weeks prior to the first dose of CMP-001)
8. Platelet count >= 100,000/mm^3 (within 4 weeks prior to the first dose of CMP-001)
9. Hemoglobin concentration >= 9 g/dL (within 4 weeks prior to the first dose of CMP-001)
10. Total bilirubin =< 1.5 times the upper limit of normal (ULN) with the following exception: subjects with Gilbert Disease serum bilirubin >= 3 times ULN (within 4 weeks prior to the first dose of CMP-001)
11. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 times the ULN or =< 5 times the ULN for patients with active liver metastases (within 4 weeks prior to the first dose of CMP-001)
12. Serum creatinine =< 1.5 times the ULN or calculated creatinine clearance >= 40 mL/min (>= 0.67 mL/sec) using the Cockcroft-Gault equation (within 4 weeks prior to the first dose of CMP-001)
13. Subjects should have an international normalized ratio (INR) or a partial thromboplastin time (PTT) =< 1.5 x ULN unless the subject is receiving anticoagulant therapy (within 4 weeks prior to the first dose of CMP-001). Subjects on anticoagulant therapy should have a prothrombin time (PT) or PTT within therapeutic range of intended use and no history of severe hemorrhage. Patients who require therapeutic anticoagulation and cannot discontinue anticoagulation safely during the day prior, day of, and day after injection are excluded. Patients requiring anticoagulation with warfarin are excluded unless they can be transitioned to an alternative anticoagulant (e.g., low molecular weight heparin or direct oral anticoagulants) prior to enrollment. Antiplatelet agents (e.g., aspirin, clopidogrel, etc.) are not considered anticoagulants for the purposes of this study (i.e., they are allowed)
14. Willingness to provide pre- and post-treatment fresh tumor biopsies, if safe and medically feasible
15. Male subjects must be surgically sterile or must agree to use adequate method of contraception from the time of consent until at least 120 days after the last dose of CMP-001
16. Willingness and ability of the subject to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions
17. Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, immunotherapy, or investigational therapy) for the treatment of cancer >= 2 weeks before the start of study therapy. (No radiotherapy to CMP-001 injection site within 4 weeks)
18. Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation

Treatment Sites in Georgia